Salam Amar M
Hamad Medical Corporation, PO Box 3050, Doha, Qatar.
Expert Rev Cardiovasc Ther. 2012 Nov;10(11):1345-9. doi: 10.1586/erc.12.118.
Dronedarone is a new antiarrhythmic currently approved for use among patients with nonpermanent atrial fibrillation (AF) based on the positive results of the ATHENA trial. Dronedarone was recently investigated in the PALLAS (Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy) trial, a landmark trial that evaluated treatment with dronedarone compared with placebo among older patients with permanent AF. The trial was terminated early due to a significant increase in adverse cardiovascular events among dronedarone-treated patients. In this article, the trial is presented and the significance and practical implications of the results in the management of older patients with AF briefly discussed.
决奈达隆是一种新型抗心律失常药物，基于ATHENA试验的阳性结果，目前已被批准用于非永久性心房颤动（AF）患者。决奈达隆最近在PALLAS（在标准治疗基础上加用决奈达隆的永久性心房颤动结局研究）试验中接受了研究，这是一项具有里程碑意义的试验，评估了在永久性AF老年患者中决奈达隆与安慰剂治疗的效果。该试验因决奈达隆治疗组患者不良心血管事件显著增加而提前终止。本文介绍了该试验，并简要讨论了结果在老年AF患者管理中的意义和实际影响。
